ClinicalTrials.gg
Sign In
Drug

Lutetium-177 clinical trials

studies test it
41
open now
26
in phase 3
3
first study started
2009

How each study uses Lutetium-177 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the Lutetium-177 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Approvals

The first approval found in each region, with its record

United States
Not in FDA's approval records
European Union
Not in EMA's list of EU-wide authorisations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

[177Lu]Lu-NeoB
4
[177Lu]Lu-PSMA-617
3
Lutathera
3
Lutetium[177Lu] Oxodotreotide Injection
3
lutetium neoB
2

Development codes

FML539
1
AAA602
1

Studies by the year they started

41 studies that test it; most in 2024 (11)

Studies that test Lutetium-177, by start year
YearStudies
20091
20225
20238
202411
20256
202610

By phase

A phase 1/2 study counts in both.

Early Phase 1
8
Phase 1
23
Phase 2
14
Phase 3
3
Phase 4
1

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Breast Neoplasms
6
Prostatic Neoplasms
6
Neuroendocrine Tumors
3
Glioblastoma
2
Carcinoma, Non-Small-Cell Lung
2
Pheochromocytoma
1
Colorectal Neoplasms
1
Meningioma
1
Lung Neoplasms
1

Who runs them

Industry 24 · Other 17

Novartis Pharmaceuticals (9) · Sinotau Pharmaceutical Group (3) · Beijing Tiantan Hospital (2) · Blue Earth Therapeutics Ltd (2) · Sichuan Baili Pharmaceutical Co., Ltd. (2) · Nantes University Hospital (1) · Providence Health & Services (1) · Advanced Accelerator Applications (1)

Often tested with

Tested in the same studies.

Capecitabine (1) · Lutetium Lu 177 dotatate (1) · Metoclopramide (1) · Cabozantinib (1) · Imp-288 (1) · Indium-111 (1) · Actinium-225 (1) · Gallium-68 (1)

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 12, 2 in phase 3

Studies that test Lutetium-177, phase 3 first.

Studies

Open first, then newest update. How each study uses Lutetium-177 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 41

See all 41 studies that test Lutetium-177 →

Codes

What other systems call Lutetium-177 · ClinicalTrials.gg INT000625

  • MeSH (NLM) C000615061Lutetium-177Confirmed ClinicalTrials.gov, NLM
  • UNII (FDA) BRH40Y9V1QLUTETIUM LU-177Confirmed NLM, Wikidata
  • Wikidata Q18882670lutetium-177Confirmed NLM, Wikidata
  • DrugBank DB13982One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.